"Yes, for Covid-19 we have a gold standard test, the PCR test that identifies the virus itself and has a relatively high sensitivity and specificity (although note that it’s not perfect)." If there is a slight hitch/holdup/gremlin to deal with is it going to be the "specificity" Tony alludes to being not perfect with the PCR test. In other words are the powers that decide to approve as a diagnostic tool going to block that approval due to that specificity "not being perfect" issue In that case one would think then that the lesser approval of a "screening tool approval" would almost be a given...if there is such a thing as "almost a given" when it comes to anything to do with the FDA. Great report Red...much appreciated by all I am sure! Go RAP! Lets get the SP back up through 15 cents again by end of Sept. Reminder...don't forget the stuff that is actually occurring with RAP with several more telehealth sign ons coming soon and then the progress reports from Illara, Medgate, Alodokter and Doctors on Demand... SARs 2 detection approval may or may not come to pass but the main game for now is RAP's known advances and revenue creators. This company now has a whole different vibe about it...big 2022 year of advancement and progress coming up!
RAP Price at posting:
7.4¢ Sentiment: Buy Disclosure: Held
